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(QALY) for etanercept compared with NST. Patients considered
had chronic plaque psoriasis, PASI of 10–12 and any DLQI value
at baseline. Response rates were taken from a pooled analysis of
three studies of etanercept. Utility gain associated with response
was assessed using patient level DLQI change mapped to EQ5D.
Clinical and quality of life outcomes were extrapolated to a time
horizon of ten years. Costs were estimated from a UK payer
perspective including drug cost, administration visits and hospi-
tal stay for treatment failures. Probabilistic sensitivity analysis
was undertaken. RESULTS: The model estimated incremental
cost per QALY gained compared with NST to be: £2,850 (95%
CI: Dominant to £6,084) for etanercept 25 mg biw and £10,351
(£7,056, £15,911) for etanercept 50 mg biw. Cost-effectiveness
was sensitive to the duration of treatment holiday and response
rate after therapy interruption. Cost per QALY gained in patients
with baseline PASI in the range 10–72 and poor quality of life at
baseline has previously been reported to be £3,299 for etanercept
25 mg biw and £10,923 for etanercept 50 mg biw. CONCLU-
SIONS: The model found treatment of a less severe psoriasis
population to be cost-effective. Cost-effectiveness was compa-
rable to ﬁndings in patients with more severe disease and poor
quality of life at baseline.
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OBJECTIVES: To assess the cost-effectiveness of Food for
Special Medical Purposes (FSMP) for the prevention of malnu-
trition in patients undergoing abdominal surgery from the per-
spective of the society in The Netherlands. METHODS: The
costs and beneﬁts of the two treatment strategies were assessed
using a linear decision analytic model reﬂecting treatment pat-
terns and outcomes in abdominal surgery. The model structure
allowed for differences in costs and length of stay. The incremen-
tal cost difference was based on costs associated with cost of
FSMP and hospitalization. Clinical probabilities and resource
utilization were based on clinical trials and published literature;
cost data were from ofﬁcial price tariffs. RESULTS: The use of
FSMP reduces the costs from €3318 to €3066, which corre-
sponds with a €252 (7.6%) cost savings per patient. The addi-
tional costs of FSMP are more than balanced by a reduction on
hospitalization costs. The hospitalization costs reduce from
€3318 to €3044 per patient, which is a 8.3% cost saving and
corresponds with 0.72 days reduction in LOS. The use of FSMP
would lead to an annual cost saving of €40.4 million based on the
number of 160,283 abdominal procedures per year in The Neth-
erlands. Sensitivity analyses were performed on all parameters,
including length of stay and per diem costs. The results showed
that the use of FSMP in all sensitivity analyses remain cost saving
compared to “no use” of FSMP. A threshold analysis on the
length of stay shows that at length of stay of 0.64 days, the use
of FSMP is still cost-effective. CONCLUSIONS: The use of
FSMP is a very cost-effective treatment in The Netherlands and is
dominant over standard care without FSMP: cost savings and
higher effectiveness.
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OBJECTIVES: To perform a CE evaluation of the use of CHOP
vs R-CHOP for the treatment of aggressive NHL stages III
and IV. METHODS: After a review of the medical literature
about the economic impact of NHL treatment, we performed an
analysis of the resources consumed by 116 patients with the
diagnostic of NHL during 2004 in the Mex-INCan. The eco-
nomic evaluation was done using an hypothetical cohort simu-
lation through a ﬁve years by means of Markov Model with
monthly transitions, using a ﬁve percent discount rate. The
model included 11 health status: Diagnostic; 1st-line treatment,
1st-remission, 1st-relapse, 1st-progression, 2nd-line treatment
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